RT Journal Article
SR Electronic
T1 Microbial contributions to oxalate metabolism in health and disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.27.20018770
DO 10.1101/2020.01.27.20018770
A1 Liu, Menghan
A1 Devlin, Joseph C.
A1 Hu, Jiyuan
A1 Volkova, Angelina
A1 Battaglia, Thomas W.
A1 Byrd, Allyson
A1 Loke, P’ng
A1 Li, Huilin
A1 Ruggles, Kelly V.
A1 Tsirigos, Aristotelis
A1 Blaser, Martin J.
A1 Nazzal, Lama
YR 2020
UL http://medrxiv.org/content/early/2020/01/29/2020.01.27.20018770.abstract
AB Over-accumulation of oxalate in humans may lead to nephrolithiasis and nephrocalcinosis. Humans lack endogenous oxalate degradation pathways (ODP), but intestinal microbiota can degrade oxalate and protect against its absorption. However, the particular microbes that actively degrade oxalate in vivo are ill-defined, which restricts our ability to disentangle the underlying taxonomic contributions. Here we leverage large-scale multi-omics data (>3000 samples from >1000 subjects) to show that the human microbiota in health harbors diverse ODP-encoding microbial species, but an oxalate autotroph-Oxalobacter formigenes- dominates this function transcriptionally. Patients with Inflammatory Bowel Disease (IBD) are at significantly increased risk for disrupted oxalate homeostasis and calcium-oxalate nephrolithiasis. Here, by analyzing multi-omics data from the iHMP-IBD study, we demonstrate that the oxalate degradation function conferred by the intestinal microbiota is severely impaired in IBD patients. In parallel, the enteric oxalate levels of IBD patients are significantly elevated and associated with intestinal disease severity, which is consistent with the clinically known nephrolithiasis risk. The specific changes in ODP expression by several important taxa suggest that they play different roles in the IBD-induced nephrolithiasis risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by U01AI22285, R01DK110014, and the Rare Kidney Stone Consortium (U54 DK083908) from the National Institutes of Health, by the C & D and Zlinkoff Funds, Oxalosis and Hyperoxaluria Foundation-American Society of Nephrology career development grant, and the TransAtlantic Partnership of the Fondation LeDucq. We thank Dr. David Goldfarb, Dr. David Fenyo, Dr. Victor Torres, Dr. Joao Xavier and Xuhui Zheng for their helpful comments.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource code of the pipeline can be found on Github via https://github.com/ml3958/FindTaxaCtrbt. Downstream analyses scripts are available per request. https://github.com/ml3958/FindTaxaCtrbt